Genetic Diagnostic Centre

gdc-egypt.com

Genetic Diagnostic Center is a leading Egyptian medical center dedicated to delivering innovative medical genetics services for patients and other healthcare providers. In GDC, we combine 50 years of experience with the latest cutting-edge technologies to offer a quality driven performance in Cytogenetics, Molecular Genetics, Hematopathology, Flow Cytometry and Immunohistochemistry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Medical

PATENT AWARDED FOR PRIMARY TEMPLATE-DIRECTED AMPLIFICATION, FURTHER STRENGTHENING BIOSKRYB GENOMICS’ CORE TECHNOLOGIES

Businesswire | August 21, 2023

news image

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced the issuance of a composition of matter patent, US Patent 11,643,682 by the U.S. Patent and Trademark Office related to its novel Primary Template-Directed Amplification (PTA) method and applications for research, diagnostics, and treatment. The patent is exclusively licensed to BioSkryb by St. Jude Children&rs...

Read More

Cell and Gene Therapy, Industrial Impact

EVAXION AND PANTHERNA REVEALS PROMISING PRECLINICAL PROOF OF CONCEPT FOR COMBINED TECHNOLOGIES

Evaxion | February 10, 2023

news image

Evaxion Biotech A/S, a clinical-phase biotech company specializing in enhancing AI-powered immunotherapies, and Pantherna Therapeutics GmbH, a biopharmaceutical company developing enhanced nanoparticle solutions for delivering and expressing mRNA therapeutics, announced a preclinical proof of concept for the combination of their key technologies. Using Pantherna's unique lipid nanoparticle mRNA technology (PTXLNP®, PTXmRNA®), tumor neoantigens discovered by Evaxion&#...

Read More

Cell and Gene Therapy, AI

BENEVOLENTAI PROGRESSES BEN-34712 FOR THE POTENTIAL TREATMENT OF ALS INTO IND-ENABLING STUDIES

Businesswire | June 05, 2023

news image

BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. Impaired retinoic acid signalling has bee...

Read More

Industrial Impact

SIRONA BIOCHEM SIGNS INTERNATIONAL PARTNERSHIP AGREEMENT WITH WANBANG BIOPHARMACEUTICALS

Sirona Biochem Corp. | November 24, 2022

news image

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence. Wanbang and Sirona initially signed a licensing agreement for TFC-039, w...

Read More
news image

MedTech, Medical

PATENT AWARDED FOR PRIMARY TEMPLATE-DIRECTED AMPLIFICATION, FURTHER STRENGTHENING BIOSKRYB GENOMICS’ CORE TECHNOLOGIES

Businesswire | August 21, 2023

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced the issuance of a composition of matter patent, US Patent 11,643,682 by the U.S. Patent and Trademark Office related to its novel Primary Template-Directed Amplification (PTA) method and applications for research, diagnostics, and treatment. The patent is exclusively licensed to BioSkryb by St. Jude Children&rs...

Read More
news image

Cell and Gene Therapy, Industrial Impact

EVAXION AND PANTHERNA REVEALS PROMISING PRECLINICAL PROOF OF CONCEPT FOR COMBINED TECHNOLOGIES

Evaxion | February 10, 2023

Evaxion Biotech A/S, a clinical-phase biotech company specializing in enhancing AI-powered immunotherapies, and Pantherna Therapeutics GmbH, a biopharmaceutical company developing enhanced nanoparticle solutions for delivering and expressing mRNA therapeutics, announced a preclinical proof of concept for the combination of their key technologies. Using Pantherna's unique lipid nanoparticle mRNA technology (PTXLNP®, PTXmRNA®), tumor neoantigens discovered by Evaxion&#...

Read More
news image

Cell and Gene Therapy, AI

BENEVOLENTAI PROGRESSES BEN-34712 FOR THE POTENTIAL TREATMENT OF ALS INTO IND-ENABLING STUDIES

Businesswire | June 05, 2023

BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. Impaired retinoic acid signalling has bee...

Read More
news image

Industrial Impact

SIRONA BIOCHEM SIGNS INTERNATIONAL PARTNERSHIP AGREEMENT WITH WANBANG BIOPHARMACEUTICALS

Sirona Biochem Corp. | November 24, 2022

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence. Wanbang and Sirona initially signed a licensing agreement for TFC-039, w...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us